Bafna Pharmaceuticals Share Price Today (BAFNAPH)
TODAY IN ONE LINE
With a market cap of ₹562.19 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Bafna Pharmaceuticals flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Earnings GrowthEPS (TTM) grew by a solid 95.0% YoY
- ●Quarterly OutperformanceLatest quarter Sales up 30.9% and Profit up 53.9%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
No red flags identified
Latest Bafna Pharmaceuticals News
What changed recently?
Recent events, corporate actions, and announcements.
Bafna Pharmaceuticals Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Bafna Pharmaceuticals Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Bafna Pharmaceuticals Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Bafna Pharmaceuticals Limited — derived from the live tape, not yesterday's close.
Bafna Pharmaceuticals Limited last traded at ₹174.58 with an intraday range of ₹174.58–₹213.36 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹174.58| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 277.99 | +103.41 | +59.24% |
| R3 | 239.21 | +64.63 | +37.02% |
| R2 | 226.29 | +51.71 | +29.62% |
| R1 | 200.43 | +25.85 | +14.81% |
| PIVOT | 187.51 | 12.93 | 7.40% |
| CURRENT | 174.58 | — | — |
| S1 | 161.65 | -12.93 | -7.40% |
| S2 | 148.73 | -25.85 | -14.81% |
| S3 | 122.87 | -51.71 | -29.62% |
| S4 | 84.09 | -90.49 | -51.83% |
BAFNAPH is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹–₹
Trading Below opening range, showing Bearishness
Bafna Pharmaceuticals Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Bafna Pharmaceuticals Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Bafna Pharmaceuticals Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹562.19 Cr. and reported EPS of ₹4.09.
| Metric | Mar 2019 | Mar 2020 |
|---|---|---|
| Revenue from Operations | 43 | 42 ▼ 2.0% |
| Sales Growth YoY %Derived | — | -2.04% |
| Other Income | 1 | 0 ▼ 60.9% |
| Total Income | 44 | 43 ▼ 2.9% |
| 35 | 27 ▼ 21.8% | |
| Gross ProfitDerived | 9 | 15 ▲ 75.8% |
| Gross Margin %Derived | 20.27% | 36.37% |
| 22 | 14 ▼ 35.7% | |
| EBITDA (Operating Profit)Derived | -13 | 1 ▲ 109.2% |
| OPM %Derived | -30.77% | 2.88% |
| 7 | -19 ▼ 390.3% | |
| Profit Before Tax (PBT) | -17 | -24 ▼ 41.4% |
| 1 | — ▼ 100.0% | |
| Effective Tax %Derived | -6.18% | — |
| Total Profit for Period | -18 | -25 ▼ 34.8% |
| Net Profit (Owner's PAT)Derived | -18 | -25 ▼ 34.8% |
| Net Profit Margin %Derived | -42.32% | -58.22% |
| PAT Growth YoY %Derived | — | -34.76% |
| Earnings Per Share (EPS ₹) | -7.76 | -104.54 ▼ 1247.2% |
| Diluted Shares Outstanding (Cr) | 2 | 0 ▼ 90.0% |
| Share of Profit from Associates/JVs | — | -0 |
| Other Comprehensive Income (Net of Tax) | -1 | — ▲ 100.0% |
| Total Expenses (incl. D&A & Interest) | 61 | 67 ▲ 9.6% |
| Material Cost % of RevenueDerived | 76.79% | 71.21% |
| Employee Cost % of RevenueDerived | 20.79% | 24.14% |
| Other Cost % of RevenueDerived | 30.26% | 9.36% |
| Interest Coverage (x)Derived | -7.91x | -21.40x |
| Period | Mar 2019 | Mar 2020 | Trend |
|---|---|---|---|
| Revenue from Operations | 43 | 42 ▼ 2.0% | |
| Sales Growth YoY %Derived | — | -2.04% | |
| Other Income | 1 | 0 ▼ 60.9% | |
| Total Income | 44 | 43 ▼ 2.9% | |
35 | 27 ▼ 21.8% | ||
| Gross ProfitDerived | 9 | 15 ▲ 75.8% | |
| Gross Margin %Derived | 20.27% | 36.37% | |
22 | 14 ▼ 35.7% | ||
| EBITDA (Operating Profit)Derived | -13 | 1 ▲ 109.2% | |
| OPM %Derived | -30.77% | 2.88% | |
7 | -19 ▼ 390.3% | ||
| Profit Before Tax (PBT) | -17 | -24 ▼ 41.4% | |
1 | — ▼ 100.0% | ||
| Effective Tax %Derived | -6.18% | — | |
| Total Profit for Period | -18 | -25 ▼ 34.8% | |
| Net Profit (Owner's PAT)Derived | -18 | -25 ▼ 34.8% | |
| Net Profit Margin %Derived | -42.32% | -58.22% | |
| PAT Growth YoY %Derived | — | -34.76% | |
| Earnings Per Share (EPS ₹) | -7.76 | -104.54 ▼ 1247.2% | |
| Diluted Shares Outstanding (Cr) | 2 | 0 ▼ 90.0% | |
| Share of Profit from Associates/JVs | — | -0 | |
| Other Comprehensive Income (Net of Tax) | -1 | — ▲ 100.0% | |
| Total Expenses (incl. D&A & Interest) | 61 | 67 ▲ 9.6% | |
| Material Cost % of RevenueDerived | 76.79% | 71.21% | |
| Employee Cost % of RevenueDerived | 20.79% | 24.14% | |
| Other Cost % of RevenueDerived | 30.26% | 9.36% | |
| Interest Coverage (x)Derived | -7.91x | -21.40x |
Bafna Pharmaceuticals segment analysis : revenue and profit mix.
Disclosed business segments at Bafna Pharmaceuticals with their share of revenue and profit, switchable between consolidated and standalone reporting.
Bafna Pharmaceuticals discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Bafna Pharmaceuticals Limited.
Our AI distills the core fundamental drivers supporting Bafna Pharmaceuticals Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Bafna Pharmaceuticals Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Bafna Pharmaceuticals Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Bafna Pharmaceuticals Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Bafna Pharmaceuticals Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Bafna Pharmaceuticals Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Bafna Pharmaceuticals Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Bafna Pharmaceuticals Limited stood at 54.7% of traded volume, against a 20-day average of 72.6%.
Bafna Pharmaceuticals announcements: results, concalls, ratings, M&A.
Filings Bafna Pharmaceuticals sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Bafna Pharmaceuticals files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 42 documents below.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Bafna Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 for the…
Disclosure under SEBI Takeover Regulations
Bafna Pharmaceuticals Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Trading Window
Bafna Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Retirement
Bafna Pharmaceuticals Limited has informed the Exchange about retirement of Mr. Navin Kumar (DIN: 08778662) as an Independent Director of the Company…
Copy of Newspaper Publication
Bafna Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication for the Audited Financial Results of the Company for the…
Investor decks & rating reports.
Bafna Pharmaceuticals dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Bafna Pharmaceuticals has declared, sequenced by announce and record date.
Bafna Pharmaceuticals corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Bafna Pharmaceuticals Limited: business, sector, key facts.
What Bafna Pharmaceuticals Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Bafna Pharmaceuticals Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: BAFNAPH, BSE: 532989.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Bafna Pharmaceuticals Limited (BAFNAPH).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Bafna Pharmaceuticals Limited (BAFNAPH)?
The current share price of Bafna Pharmaceuticals Limited (BAFNAPH) is ₹174.58. Today, the stock has declined by ₹19.39 (10.00%), trading in a range of ₹174.58 to ₹213.36. The stock opened at ₹209.7 with a trading volume of 2,83,731 shares.
02Is Bafna Pharmaceuticals Limited stock a good investment for long-term?
Bafna Pharmaceuticals Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹562.19 crores, P/E ratio of 0.00, ROE of 11.54%, and ROCE of -3.00%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Bafna Pharmaceuticals Limited stock?
The 52-week high price of Bafna Pharmaceuticals Limited (BAFNAPH) is ₹213.36, while the 52-week low is ₹78.18. Currently trading at ₹174.58, the stock is 71.3% away from its 52-week low and 18.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Bafna Pharmaceuticals Limited stock at the current price?
Whether to buy Bafna Pharmaceuticals Limited stock at ₹174.58 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 0.00. Today's performance shows a loss of 10.00%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Bafna Pharmaceuticals Limited and when is the next dividend?
Bafna Pharmaceuticals Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹174.58, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Bafna Pharmaceuticals Limited?
Bafna Pharmaceuticals Limited's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 0.00, ROE: 11.54%, ROCE: -3.00%, Dividend Yield: 0.00%, EPS: ₹4.09, Book Value: ₹38.54, and Debt-to-Equity: 0.39. The company's market cap stands at ₹562.19 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Bafna Pharmaceuticals Limited stock performing today in the market?
Bafna Pharmaceuticals Limited stock opened at ₹209.7 and is currently trading at ₹174.58, showing a decline of ₹19.39 (10.00%). The intraday high is ₹213.36 and low is ₹174.58. The trading volume stands at 2,83,731 shares, indicating moderate market participation today.
08What is the P/E ratio of Bafna Pharmaceuticals Limited and what does it indicate?
Bafna Pharmaceuticals Limited has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹4.09, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Bafna Pharmaceuticals Limited (BAFNAPH) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.